Skip to main content

Advertisement

SpringerLink
Log in

Society of Surgical Oncology Presidential Address: The War on Cancer—Shifting from Disappointment to New Hope

  • Translational Research and Biomarkers
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

References

  1. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–13.

    CAS  PubMed  Google Scholar 

  2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960–6.

    Article  CAS  PubMed  Google Scholar 

  3. Stewart DJ, Kurzrock R. Cancer: the road to Amiens. J Clin Oncol. 2009;27(3):328–33.

    Article  PubMed  Google Scholar 

  4. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 1994;124(4):619–26.

    Article  CAS  PubMed  Google Scholar 

  5. Golubovskaya VM, Kweh FA, Cance WG. Focal adhesion kinase and cancer. Histol Histopathol. 2009;24(4):503–10.

    CAS  PubMed  Google Scholar 

  6. Cance WG, Golubovskaya VM. Focal adhesion kinase versus p53: apoptosis or survival? Sci Signal. 2008;1(20):pe22.

    Article  PubMed  Google Scholar 

  7. Burdelya LG, Krivokrysenko VI, Tallant TC, et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science. 2008;320(5873):226–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA

    William G. Cance MD

Authors
  1. William G. Cance MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William G. Cance MD.

Additional information

Dr. Cance is a major stock shareholder with CureFAKtor Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cance, W.G. Society of Surgical Oncology Presidential Address: The War on Cancer—Shifting from Disappointment to New Hope. Ann Surg Oncol 17, 1971–1978 (2010). https://doi.org/10.1245/s10434-010-0987-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-010-0987-2

Keywords

Search

Navigation